CTA-PB

Business Context and Reporting Period

Company: E. I. du Pont de Nemours and Company (DuPont)
Filing Type: Form 8-K (Current Report)
Reporting Period: First Quarter ended March 31, 2009
Date of Report: April 21, 2009

DuPont reported first-quarter earnings in line with guidance despite a severe decline in global industrial demand. The company highlighted strong performance in its Agriculture & Nutrition and pharmaceuticals segments, which offset losses in industrial segments driven by a global recession, inventory de-stocking, and currency headwinds.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Decline: Consolidated sales fell 20% year-over-year, driven by a 19% volume decrease and a 5% negative currency impact. Local prices increased 5% but were insufficient to offset volume and currency losses.
• Segment Divergence:
  • Agriculture & Nutrition: Sales up 6% and Pre-Tax Operating Income (PTOI) up 8% to $852 million, driven by seed pricing and North American volumes.
  • Industrial Segments: Significant declines across Coatings & Color Technologies (Sales -30%, PTOI loss of $19M), Electronic & Communication Technologies (Sales -32%, PTOI loss of $54M), Performance Materials (Sales -45%, PTOI loss of $146M), and Safety & Protection (Sales -24%, PTOI down to $72M).
• Cost Structure: Fixed costs as a percent of sales increased to 43.4% from 35.9% due to lower sales volumes, though the company implemented $250 million in fixed cost reductions to mitigate losses.
• Liquidity: Cash and cash equivalents decreased by $1.26 billion during the quarter, primarily due to operating cash outflows and dividend payments, partially offset by net borrowings of $433 million.

Guidance, Outlook, and Management Commentary

• Revised 2009 Outlook: DuPont lowered its full-year 2009 earnings guidance to a range of $1.70 to $2.10 per share (excluding significant items), down from previous expectations. This reflects continued weak demand in non-agricultural markets and currency impacts.
• Cost and Capital Actions:
  • Increased 2009 fixed cost reduction goal to $1 billion (up from $730 million).
  • Reduced 2009 planned capital expenditures by an additional $200 million to $1.4 billion (30% below 2008 levels).
  • Working capital reduction projects are underway, targeting a $1 billion improvement over 2008.
• Cash Flow Outlook: Full-year free cash flow remains projected at approximately $2.5 billion.
• Management Commentary: CEO Ellen J. Kullman emphasized that strong performance in agriculture and pharmaceuticals, combined with aggressive cost management, helped offset the "largest decline in industrial demand in decades." The company is taking preemptive actions to preserve cash generation and position for a market rebound.
• Risks: Continued global recession, inventory de-stocking, foreign currency exchange rate fluctuations, and weak demand in construction, automotive, and general industrial markets.

Investor Verification Checklist

• Verify the sustainability of the $1 billion fixed cost reduction target and the timeline for additional restructuring actions expected in Q2 2009.
• Monitor the cash burn rate given the $1.26 billion decrease in cash equivalents in Q1 and the reliance on borrowings to fund operations and dividends.
• Assess the resilience of the Agriculture & Nutrition segment as the primary growth driver amidst broader industrial weakness.
• Review the impact of currency fluctuations on future earnings, as a 5% negative impact was recorded in Q1.
• Confirm the execution of the reduced capital expenditure plan ($1.4 billion) and its effect on long-term growth investments in high-margin areas like seed products and photovoltaics.